Loading...
Please wait, while we are loading the content...
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
| Content Provider | Scilit |
|---|---|
| Author | Passamonti, Francesco Maffioli, Margherita Cervantes, Francisco Vannucchi, Alessandro Maria Morra, Enrica Barbui, Tiziano Caramazza, Domenica Pieri, Lisa Rumi, Elisa Gisslinger, Heinz Knoops, Laurent Kiladjian, Jean-Jacques Mora, Barbara Hollaender, Norbert Pascutto, Cristiana Harrison, Claire Cazzola, Mario |
| Copyright Year | 2014 |
| Description | Key PointsPatients with primary myelofibrosis and intermediate-2 or high IPSS risk have a median life expectancy of 4 years or less. PMF patients with higher IPSS risks who receive ruxolitinib treatment have longer survival than those who receive conventional therapy. |
| Related Links | https://core.ac.uk/reader/34108097 |
| Ending Page | 1835 |
| Page Count | 3 |
| Starting Page | 1833 |
| DOI | 10.1182/blood-2013-12-544411 |
| Journal | Blood |
| Issue Number | 12 |
| Volume Number | 123 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2014-03-20 |
| Access Restriction | Open |
| Subject Keyword | Hematology Treatment Survival Comfort History Primary Myelofibrosis Pmf Ruxolitinib Dipss Longer Pointspatients Journal: Blood (Vol- 121, Issue- 12) |
| Content Type | Text |
| Resource Type | Article |